HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hawaiian Sunscreen Ban On Brink Of Passage; Lawmakers Hashing Out Final Details

This article was originally published in The Rose Sheet

Executive Summary

Conferees from the state’s House and Senate will meet in an effort to resolve differences in legislation to ban the sale of oxybenzone- and octinoxate-containing sunscreens due to environmental concerns. A consensus version of the bill must be available for final reads by April 26.

You may also be interested in...

FDA Says No Decision Reached Yet On Oxybenzone/Octinoxate Ban Petition

According to industry, available scientific evidence regarding oxybenzone’s and octinoxate’s effects on coral does not support their removal from the OTC sunscreen drug monograph’s list of permitted UV filters, and FDA is fully compliant with federal environmental laws, contrary to the Center for Biological Diversity’s suggestions. FDA says the petition raises complex issues requiring extensive review.

Suns Sets In Hawaii On Sunscreens Containing Octinoxate, Oxybenzone

PCPC Expands Safety Focus To Answer Growing Environmental Concerns

The Personal Care Products Council is no stranger to risk assessment to support ingredients’ safety for consumers, but with environmental concerns on the rise, the group is working to develop tools for addressing that side of the safety equation. “We are going to have to have a strong risk assessment method to defend the ingredients that you all really need,” says PCPC’s Chief Scientist Beth Jonas.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts